
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc. demonstrates a positive outlook as its therapy, deramiocel, has shown a favorable long-term benefit-risk profile and has been well tolerated with no new safety signals. The ongoing partnership is expected to extend the company's operational runway, facilitating preparations for potential commercial launches and manufacturing scale-up, particularly in Europe. Furthermore, the focus on DMD-cardiomyopathy enhances the de-risking of the company's biolytical application (BLA) submission plans, potentially expediting deramiocel's market entry and driving partner-driven pre-commercial activities.
Bears say
Capricor Therapeutics Inc. is experiencing challenges due to mixed clinical trial results, evidenced by the decline in Performance of the Upper Limb 2.0 (PUL 2.0) total score among patients treated with deramiocel compared to untreated individuals. The average annual decline for deramiocel-treated patients showed only a marginal reduction in disease progression, highlighting uncertainties about the long-term efficacy of the therapy. Additionally, concerns regarding the company's ability to secure adequate funding for ongoing clinical development may further hinder its progress and negatively impact future stock performance.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares